Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQFI.L Regulatory News (QFI)

  • There is currently no data for QFI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Joint Development Agreement - MSC Shipmanagement

21 Jan 2021 07:00

RNS Number : 3888M
Quadrise Fuels International PLC
21 January 2021
 

21 January 2021

 

Quadrise Fuels International plc

("Quadrise", "QFI" or the "Company")

 

 

JOINT DEVELOPMENT AGREEMENT WITH MSC SHIPMANAGEMENT LIMITED

 

Quadrise is pleased to announce it has signed a Joint Development Agreement ("JDA") with MSC Shipmanagement Limited of Cyprus ("MSC"), a 100% subsidiary of MSC Mediterranean Shipping Company SA headquartered in Geneva, to carry out an MSAR® Operational Trial (the "Trial") on commercial container vessels in the MSC global fleet commencing in 2021 with, subject to further agreement, subsequent commercial rollout upon success. The MSC Group is one of the world's largest cargo shipping and cruise line companies.

 

Initial activities under the JDA will include project initiation, definition, high-level scoping and feasibility activities ("Initial Activities") of the overall Trial. The Initial Activities are to be completed within 3 months.

 

Contingent on the outcome of the Initial Activities the parties will progress and define the project roadmap during Q2'21 in preparation for the execution of one or more Trials commencing in H2'21 on representative commercial vessels in MSC's global fleet ("Phase 1"). Upon completion and success of Phase 1, and subject to further agreement between the parties, the JDA envisages subsequent commercial roll-out across the MSC global fleet ("Phase 2").

 

Phase 1 will see the testing of MSAR® fuel in a large MAN ME and/or a Wärtsilä/WinGD Flex 2-stroke engine so as to obtain Letter Of No Objection ("LONO") approvals from the respective engine manufacturers. Phase 1 testing may also incorporate testing of QFI's new bioMSARTM biofuel.

 

In the event that the Trial(s) and LONO approval(s) are successful under Phase 1, and subject to further commercial agreements to be agreed between the parties, the parties would seek to rollout MSAR® fuel, and potentially bioMSARTM, for the MSC global fleet.

 

The JDA will capitalise on QFI's skills in emulsion fuel application and use in large diesel engines. MSC will contribute its vast shipping industry experience and provide technical expertise relating to naval architecture, machinery systems, fuels, exhaust gas cleaning systems, emissions and technical ship management. MSC is at the forefront of exploring and trialling fuels and technologies to help decarbonise the international shipping industry.

Commenting on this agreement Jason Miles, CEO of QFI, said:

"Quadrise is delighted to have signed this agreement with MSC and we look forward to working alongside them to progress this excellent opportunity. We believe that MSC's large modern fleet installed with electronic engines and, in some cases, exhaust gas cleaning systems (scrubbers) is well positioned to realise the economic and environmental benefits of MSAR® and bioMSARTM and we look forward to realising the project and getting the trials underway in 2021."

Commenting on this agreement Prabhat Jha, Group MD & CEO of MSC Shipmanagement Ltd, said:

"MSC is looking forward to working with the Quadrise team under the JDA in 2021 to scope out the operational trials of MSAR® on our container vessels. We are particularly interested in the potential environmental benefits of MSAR® and bioMSARTM that, alongside the economic benefits, reflect our approach to operating a modern MSC fleet, and fit well with our overall future fuels strategy."

 

 

For further information, please contact:

 

Quadrise Fuels International Plc

 

Mike Kirk, Chairman

+44 (0)20 7031 7321

Jason Miles, Chief Executive Officer

ir@quadrisefuels.com

 

 

Nominated Adviser

 

Cenkos Securities plc

 

Ben Jeynes

Katy Birkin

+44 (0)20 7397 8900

 

 

Joint Brokers

 

Peel Hunt LLP

 

Richard Crichton

+44 (0)20 7418 8900

David McKeown

 

 

 

Shore Capital Stockbrokers Limited

 

Toby Gibbs

Fiona Conroy

+44 (0)20 7408 4090

 

 

Public & Investor Relations

 

FTI Consulting

 

Ben Brewerton

+44 (0)20 3727 1000

Ntobeko Chidavaenzi

 

 

The information communicated within this announcement was deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 prior to the release of this announcement. Upon the publication of this announcement, this inside information is now considered to be in the public domain. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREAAFEAFFFEAA
Date   Source Headline
31st Oct 20167:00 amRNSResult of Open Offer
28th Oct 201611:53 amRNSHolding(s) in Company
26th Oct 20164:46 pmRNSHolding(s) in Company & Director/PDMR Shareholding
18th Oct 20167:00 amRNSNew Corporate Website
14th Oct 20167:00 amRNSOpen Offer
12th Oct 20162:46 pmRNSResults of Placing
12th Oct 20167:01 amRNSProposed Placing and Proposed Open Offer
12th Oct 20167:00 amRNSFinal Results
30th Sep 20167:00 amRNSOperational Update
14th Sep 20167:00 amRNSExtension of Contracts with AkzoNobel
11th Aug 20165:20 pmRNSHolding(s) in Company
10th Aug 20168:43 amRNSMemorandum of Understanding
21st Jul 20167:00 amRNSDirectorate Change
12th Jul 20164:24 pmRNSDirector/PDMR Shareholding
5th Jul 20162:05 pmRNSDirector/PDMR Shareholding
5th Jul 20167:00 amRNSEnd of Year Update
28th Jun 20163:09 pmRNSHolding(s) in Company
13th Jun 20164:40 pmRNSSecond Price Monitoring Extn
13th Jun 20164:35 pmRNSPrice Monitoring Extension
10th Jun 20164:40 pmRNSSecond Price Monitoring Extn
10th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Apr 20165:11 pmRNSIssue of Options and Director's Dealing
1st Apr 20167:00 amRNSFurther re Directorate Change
24th Mar 20164:13 pmRNSIssue of Options and Directors' Dealings
24th Mar 20167:00 amRNSDirector/PDMR Shareholding
22nd Mar 20163:04 pmRNSHolding(s) in Company
21st Mar 20167:00 amRNSHalf Yearly Report
17th Mar 20161:11 pmRNSMarine Programme Update
3rd Mar 20164:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20164:35 pmRNSPrice Monitoring Extension
19th Feb 20164:13 pmRNSNotice of Interim Results
2nd Feb 20167:00 amRNSDirectorate Change
21st Dec 20152:24 pmRNSDirector/PDMR Shareholding
17th Dec 20154:40 pmRNSSecond Price Monitoring Extn
17th Dec 20154:35 pmRNSPrice Monitoring Extension
14th Dec 20152:23 pmRNSFeasibility Study Contract
27th Nov 20154:16 pmRNSResult of AGM
23rd Nov 20157:00 amRNSDirectorate Change
19th Nov 20157:00 amRNSUpdate re Research & Development Programmes
4th Nov 20154:47 pmRNSPosting of Annual Report and Notice of AGM
2nd Nov 20154:35 pmRNSPrice Monitoring Extension
15th Oct 20154:40 pmRNSSecond Price Monitoring Extn
15th Oct 20154:35 pmRNSPrice Monitoring Extension
12th Oct 20157:00 amRNSFinal Results
1st Oct 20155:38 pmRNSHolding(s) in Company
16th Sep 20157:00 amRNSHalf Year Update on Major Active Programmes
25th Aug 20154:41 pmRNSSecond Price Monitoring Extn
25th Aug 20154:35 pmRNSPrice Monitoring Extension
13th Aug 20154:35 pmRNSPrice Monitoring Extension
12th Aug 20154:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.